AB077. The expression and clinical significance of α-actinin-1 in prostate cancer and benign prostatic hyperplasia

Background: To investigate the expression and clinical significance of α-actinin-1 protein in prostate cancer and prostatic hyperplasia.

Methods: Collection all the clinical data of the patients of prostate cancer and prostatic hyperplasia treated in our school affiliated hospital between January 2007 and October 2014, according to certain criteria into a group filter. Immunohistochemistry method was used to detect the expression of α-actinin-1 in 30 cases of prostate cancer (PCa) tissues and 30 cases of benign prostatic hyperplasia (BPH) tissues. Western blot method was used to detect the relative expression of α-actinin-1 in 18 cases of PCa tissues and 20 cases of BPH tissues among the two groups.

Results: The result of Immunohistochemistry shows that the positive expression rate of α-actinin-1 in PCa and BPH was 76.7% and 20% respectively. The difference was statistically significant (P<0.01). And the result of Western Plot shows that the expression of α-actinin-1 in PCa tissues was significantly higher than that in BPH tissues. The difference was statistically significant (P<0.05). The expression of α-actinin-1 in PCa has statistically significant with Gleason scores and T staging (P<0.05) instead of age, serum PSA, whether there is bone metastasis, whether there is lymph node metastasis (P>0.05).

Conclusions: The expression of α-actinin-1 in PCa tissues was significantly higher than that in BPH tissues, and there may exist certain relationship with Gleason scores and T staging.

Keywords: Prostate cancer (PCa); benign prostatic hyperplasia (BPH); α-actinin-1